###begin article-title 0
Selective Down-Regulation of Nuclear Poly(ADP-Ribose) Glycohydrolase
###end article-title 0
###begin p 1
Conceived and designed the experiments: DMB RAS. Performed the experiments: DMB WY TMK KZ. Analyzed the data: DMB TMK RAS. Wrote the paper: DMB RAS.
###end p 1
###begin p 2
Current address: University of Massachusetts Medical School, Worcester, Massachusetts, United States of America
###end p 2
###begin p 3
Current address: Med-X Research Institute, Shanghai Jiaotong University, Shanghai, China
###end p 3
###begin p 4
Current address: Zhejiang University School of Medicine, Hangzhou, China
###end p 4
###begin title 5
Background
###end title 5
###begin p 6
The formation of ADP-ribose polymers on target proteins by poly(ADP-ribose) polymerases serves a variety of cell signaling functions. In addition, extensive activation of poly(ADP-ribose) polymerase-1 (PARP-1) is a dominant cause of cell death in ischemia-reperfusion, trauma, and other conditions. Poly(ADP-ribose) glycohydrolase (PARG) degrades the ADP-ribose polymers formed on acceptor proteins by PARP-1 and other PARP family members. PARG exists as multiple isoforms with differing subcellular localizations, but the functional significance of these isoforms is uncertain.
###end p 6
###begin title 7
Methods / Principal Findings
###end title 7
###begin p 8
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
Primary mouse astrocytes were treated with an antisense phosphorodiamidate morpholino oligonucleotide (PMO) targeted to exon 1 of full-length PARG to suppress expression of this nuclear-specific PARG isoform. The antisense-treated cells showed down-regulation of both nuclear PARG immunoreactivity and nuclear PARG enzymatic activity, without significant alteration in cytoplasmic PARG activity. When treated with the genotoxic agent MNNG to induced PARP-1 activation, the antisense-treated cells showed a delayed rate of nuclear PAR degradation, reduced nuclear condensation, and reduced cell death.
###end p 8
###begin title 9
Conclusions/Significance
###end title 9
###begin p 10
These results support a preferentially nuclear localization for full-length PARG, and suggest a key role for this isoform in the PARP-1 cell death pathway.
###end p 10
###begin title 11
Introduction
###end title 11
###begin p 12
###xml 40 41 40 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 236 239 236 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Schreiber1">[1]</xref>
###xml 464 467 464 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Schreiber1">[1]</xref>
###xml 569 572 569 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Zahradka1">[2]</xref>
###xml 741 742 741 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 821 824 821 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Szabo1">[3]</xref>
###xml 825 828 825 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Alano1">[5]</xref>
Poly(ADP-ribose) polymerases consume NAD+ to form poly(ADP-ribose) (abbreviated as PAR) on acceptor proteins. This post-translational modification influences protein-protein interactions and serves a variety of cell signaling functions [1]. PARP-1, the most abundant of the PARP family members, is localized to the cell nucleus and is activated by DNA damage. Activated PARP-1 forms PAR on histones, DNA repair enzymes, and proteins involved in gene transcription [1]. PARP-1 also forms PAR on PARP-1 itself, and this, under some conditions, can reduce PARP-1 activity [2]. Extensive activation of PARP-1 occurs after ischemia-reperfusion, trauma, and other conditions that cause DNA damage. In these settings, PARP-1 activation leads to NAD+ depletion, mitochondrial release of apoptosis-inducing factor, and cell death [3]-[5].
###end p 12
###begin p 13
###xml 173 176 173 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Koh1">[6]</xref>
###xml 178 181 178 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 265 268 265 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Niere1">[8]</xref>
###xml 270 273 270 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Oka1">[9]</xref>
###xml 395 398 395 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Koh1">[6]</xref>
###xml 565 569 565 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Ying1">[10]</xref>
###xml 570 574 570 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Formentini1">[17]</xref>
###xml 632 635 632 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Koh1">[6]</xref>
###xml 729 733 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-StLaurent1">[18]</xref>
###xml 911 915 911 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Cuzzocrea1">[15]</xref>
###xml 917 921 917 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Cortes1">[19]</xref>
###xml 923 927 923 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Cozzi1">[20]</xref>
###xml 627 631 <span type="species:ncbi:10090">mice</span>
###xml 735 739 <span type="species:ncbi:10090">Mice</span>
The PAR generated by PARP-1 and other PARP isoforms is degraded by poly(ADP-ribose) glycohydrolase (EC 3.2.1.143; PARG), for which there is only one identified genetic loci [6], [7]. The mitochondrial enzyme, ADP-ribosyl hydrolase, is also capable of degrading PAR [8], [9], but this is of uncertain biological significance because cells with PARG gene deletion exhibit massive PAR accumulation [6]. PARG activity can be suppressed by pharmacological inhibitors or RNAi, both of which slow the degradation of newly-formed PAR and block PARP-1 - mediated cell death [10]-[17]. However, PARG gene deletion is embryonic lethal in mice [6], and RNAi of the PARG orthologue in the nematode increases sensitivity to ionizing radiation [18]. Mice expressing a truncated PARG isoform lacking exons 2 and 3 in the regulatory domain show different effects on PARP-1 - mediated cell death in different experimental models [15], [19], [20].
###end p 13
###begin p 14
###xml 257 264 257 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g001">Fig. 1A</xref>
###xml 411 415 411 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-MeyerFicca1">[21]</xref>
###xml 581 584 581 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 922 925 922 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 927 931 927 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Tanuma1">[22]</xref>
###xml 932 936 932 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
###xml 187 192 <span type="species:ncbi:9606">human</span>
The interpretation of these somewhat conflicting observations is complicated by the existence of multiple PARG isoforms and the differing subcellular localizations of these isoforms. The human PARG gene can be processed into at least three splice variants (Fig. 1A). These splice variants yield proteins of 111 kD, 102 kD, and 99 kD. Of these, only the 111 kD isoform is preferentially localized to the nucleus [21]. However, several catalytically active smaller isoforms of PARG have been identified in cell lysates, and these account for the majority of endogenous PARG activity [7]. It remains uncertain whether these smaller species are splice variants or proteolytic fragments. Although full-length PARG can be demonstrated in cells transfected with PARG cDNA, endogenous expression of full-length PARG is not usually detectable, due either to low protein abundance or to rapid cleavage into smaller active fragments [7], [22]-[24].
###end p 14
###begin title 15
Nuclear PARG protein expression is reduced by the PARG antisense PMO targeted to exon 1.
###end title 15
###begin p 16
###xml 217 221 217 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Ame1">[27]</xref>
(A) The full-length 111 kD protein contains a nuclear localization sequence (NLS) in exon 1 and a nuclear export sequence (NES) near the carboxy terminus. The anti-PARG antibody targets the peptide fragment indicated [27]. The PARG antisense PMO was directed to the extreme 5' end of exon 1 of the full-length PARG mRNA. (B) Astrocytes are immunostained for PARG (green), and nuclei are counterstained with propidium iodide (red). Merged images demonstrate a reduction in PARG expression, mainly in the nuclei, after PARG PMO treatment, as compared to both the no PMO (Control) condition and the inverted sequence PMO (Control PMO) condition. Scale bar = 20 microm. Images are representative of 6 independent experiments with similar results.
###end p 16
###begin p 17
###xml 300 307 300 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g001">Fig. 1A</xref>
###xml 533 536 533 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
In the present study we aimed to examine the specific role of nuclear PARG activity in PARP-1 - mediated cell death by selectively blocking translation of the 111 kDa, nuclear-targeted isoform using an antisense phosphorodiamidate morpholino oligonucleotide (PMO) targeted to the 5' start of exon 1 (Fig. 1A). PARG enzymatic activity was used as the primary measure of antisense PMO efficacy in order to circumvent the difficulties inherent in identifying full-length PARG and active PARG cleavage products on standard Western blots [7]. Our findings indicate that selective down-regulation of the nuclear PARG isoform slows the rate of nuclear PAR degradation and attenuates PARP-1- mediated cell death.
###end p 17
###begin title 18
Materials and Methods
###end title 18
###begin p 19
Reagents were purchased from Sigma Chemical Co (St. Louis, MO) except where noted. Animal studies were performed in accordance with a protocol approved by the San Francisco Veterans Affairs Medical Center animal use committee.
###end p 19
###begin title 20
Cell cultures
###end title 20
###begin p 21
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Hertz1">[25]</xref>
###xml 109 112 109 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Alano1">[5]</xref>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
Primary mouse cortical astrocyte cultures were prepared by the method of Hertz [25] with minor modifications [5].
###end p 21
###begin title 22
Morpholino oligonucleotide treatments
###end title 22
###begin p 23
###xml 29 58 29 58 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGACCCGCAGCACACAGTCCCCC-3&#8242;</named-content>
###xml 318 323 <span type="species:ncbi:10090">Mouse</span>
###xml 439 444 <span type="species:ncbi:10090">Mouse</span>
The PARG antisense sequence, 5'-GGACCCGCAGCACACAGTCCCCC-3', is complementary to the 5' end of exon 1 on the full length PARG mRNA (GenBank, Accession# NM_011960), with the exception of the 3'nucleotide of the antisense sequence. The antisense sequence has no significant complementarity to other sequences in the NCBI Mouse RefSeq mRNA database. The inverted sequence also has no significant complementarity to other sequences in the NCBI Mouse RefSeq mRNA database, and was used as a negative control. For cell delivery, the PMOs (Gene Tools, Philomath, OR) were mixed with 1 microM ethoxylated polyethylenimine (EPEI) and diluted into the culture medium for a 3 hour incubation at 37degreesC. The cultures were used for experiments 2 days after PMO treatment.
###end p 23
###begin title 24
PARG activity assay
###end title 24
###begin p 25
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Menard1">[26]</xref>
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
###xml 150 152 150 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 211 213 211 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 228 230 228 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
###xml 264 268 264 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
###xml 383 385 377 379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 949 951 933 935 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1110 1112 1094 1096 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1260 1264 1244 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Ying1">[10]</xref>
###xml 1266 1270 1250 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Formentini1">[17]</xref>
###xml 178 182 <span type="species:ncbi:9913">calf</span>
Exoglycosidic PARG activity was measured by the method of Menard and Poirier [26], with minor modifications [24]. The enzyme substrate, histone-bound 14C PAR, was prepared using calf thymus DNA and histones, [U-14C] NAD (2.84x10-2 pmol / dpm), and purified PARP-1 [24]. The PARG activity assay was preceded by a 1 hour incubation at 37degreesC to allow the digestion endogenous PAR. 14C-labeled PAR was added at a concentration of 5 microM and the incubation continued for an additional 30 minutes at 37degreesC. Aliquots were removed at the initial and ending time points, and reactions were quenched with 0.1% sodium dodecyl sulfate (SDS). All aliquots were also spiked with non-radiolabeled ADP-ribose for easy UV detection after thin-layer chromatography (TLC). The aliquots were spotted onto PEI-cellulose TLC sheets, which were developed first in 100% methanol and then in 0.3 M LiCl / 0.9 M acetic acid. The ADP-ribose spots were cut out and 14C was measured with a liquid scintillation counter. In some studies, the TLC sheets were imaged using the Typhoon 9410 system (Amersham) for quantification of 14C-ADP-ribose. Similar results obtained with the two methods. With either method, ADP-ribose formation was blocked by the PARG inhibitor gallotannin [10], [17] (not shown).
###end p 25
###begin title 26
Immunocytochemistry
###end title 26
###begin p 27
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
###xml 225 229 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Ame1">[27]</xref>
###xml 255 261 <span type="species:ncbi:9986">rabbit</span>
###xml 320 326 <span type="species:ncbi:9986">rabbit</span>
###xml 335 339 <span type="species:ncbi:9925">goat</span>
Confluent astrocytes plated on glass coverslips were fixed in cold methanol / acetone. The cultures were incubated with a 1:500 dilution of anti-N-terminal PARG polyclonal antibody (generous gift of Dr. Myron Jacobson) [24], [27], or a 1:1000 dilution of rabbit anti-PAR (Trevigen), and visualized with fluorescent anti-rabbit or anti-goat IgG. For some studies, cell nuclei were counterstained with propidium iodide. Photomicrographs were obtained by confocal microscopy.
###end p 27
###begin title 28
Western blots
###end title 28
###begin p 29
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
###xml 204 209 <span type="species:ncbi:10090">mouse</span>
###xml 288 294 <span type="species:ncbi:9986">rabbit</span>
###xml 362 367 <span type="species:ncbi:10090">mouse</span>
###xml 434 439 <span type="species:ncbi:10090">mouse</span>
###xml 565 570 <span type="species:ncbi:10090">mouse</span>
###xml 579 585 <span type="species:ncbi:9986">rabbit</span>
Cultures were lysed in modified RIPA buffer, applied to a 10% resolving SDS gel, separated by electrophoresis, and transferred to PVDF membranes as described [24]. The antibody dilutions were as follows: mouse monoclonal antibody to poly(ADP-ribose) (Trevigen , Gaithersburg, MD), 1:500; rabbit polyclonal antibody to PARP-1 (Cell Signaling Technology), 1:1500; mouse monoclonal antibody to porin (Calbiochem, San Diego, CA), 1:1000; mouse monoclonal antibody to beta-actin (Sigma-Aldrich), 1:10,000. Primary antibodies were visualized with peroxidase-labeled anti-mouse or anti-rabbit IgG and chemiluminescence detection. Band intensities on each lane were normalized to the beta-actin bands on the same lane. For quantification of poly(ADP-ribosyl)ated proteins, the signal over the entire lane (approximately 20-250 kD) was measured.
###end p 29
###begin title 30
Cell fractionation
###end title 30
###begin p 31
###xml 80 84 80 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Scortegagna1">[28]</xref>
The separation of nuclear and cytoplasmic components was performed as described [28]. The purity of the nuclear and cytoplasmic fractions of each separation were tested in duplicate using Western blots stained with antibodies to the nuclear marker, PARP-1, and the mitochondrial marker, porin.
###end p 31
###begin title 32
MNNG incubations and cell survival assays
###end title 32
###begin p 33
###xml 111 112 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 133 134 133 134 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 136 137 136 137 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 150 151 150 151 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 218 219 218 219 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 276 277 276 277 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 536 540 530 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Koh2">[29]</xref>
###xml 560 563 554 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Alano1">[5]</xref>
MNNG incubations were performed in a balanced salt solution (BSS) containing (in mM): KCl, 3.1; NaCl, 134; CaCl2, 1.2; MgSO4, 1.2; KH2PO4, 0.25; NaHCO3, 15.7; HEPES, 5, glucose, 5. The BSS was equilibrated with a 5% CO2 atmosphere and the incubations were performed in a 5% CO2 37degrees incubator. Incubations were terminated after 60 minutes, except where noted, by exchange with fresh BSS. Cell survival was evaluated 24 hours later by measuring lactate dehydrogenase (LDH) activity in cell lysates, using the method of Koh and Choi [29] with modifications [5]. Cell survival in each well was calculated by normalizing LDH activity to the mean LDH activity of 4 control wells from the same 24-well plate.
###end p 33
###begin title 34
Statistical analyses
###end title 34
###begin p 35
Data are presented as means+/-standard errors. Statistical significance was assessed by using the analysis of variance (ANOVA) followed by the Student-Newman-Keuls test for comparisons between multiple treatment groups.
###end p 35
###begin title 36
Results
###end title 36
###begin p 37
###xml 140 147 140 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g001">Fig. 1A</xref>
###xml 426 433 426 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g001">Fig. 1B</xref>
###xml 123 128 <span type="species:ncbi:10090">mouse</span>
###xml 177 182 <span type="species:ncbi:10090">mouse</span>
The antisense PARG PMO was designed to target the most 5' AUG start codon, which is present only in the full-length 111 kD mouse PARG mRNA (Fig. 1A). Immunostaining for PARG in mouse astrocyte cultures treated with antisense PARG PMO showed a marked and selective loss of immunoreactivity from the nuclei of the antisense PMO-treated cells, as compared to sister cultures treated with control (invert sequence) PMO or no PMO (Fig. 1B). Controls prepared with omission of the anti-PARG antibody exhibited no immunoreactivity (not shown).
###end p 37
###begin p 38
###xml 286 289 286 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Tanuma1">[22]</xref>
###xml 296 300 296 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
###xml 479 487 479 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g002">Figure 2</xref>
###xml 1061 1064 1061 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 1066 1070 1066 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
The effect of antisense PARG PMO on full-length PARG expression was also evaluated with western blots of nuclear and cytoplasmic cell fractions; however, the western blots revealed only faint or undetectable full length PARG, consistent with prior reports of endogenous PARG expression [7], [22]-[24]. We therefore measured PARG enzymatic activity in the nuclear and cytoplasmic cell fractions to evaluate the functional effects of the antisense PARPG PMO treatment. As shown in Figure 2, the nuclear PARG specific activity (activity normalized to protein) was substantially lower in the cells treated with the antisense PMO than in cells treated with the control PMO or no PMO. By contrast, there was no significant difference in PARG cytoplasmic specific activity among the 3 treatment groups. As would be expected, there was no significant reduction in whole-cell PARG activity in the antisense-treated cultures, consistent with the relatively small contribution of nuclear protein to total cell protein and nuclear PARG activity to total cell PARG activity [7], [24].
###end p 38
###begin title 39
Nuclear PARG activity is selectively reduced by PARG antisense PMO.
###end title 39
###begin p 40
(A) Activity assays of whole-cell, nuclear, and cytoplasmic cell fractions. n = 5; * p<0.05. (B) Western blots of cell fractions showed the nuclear marker PARP-1 confined to the nuclear fraction and the mitochondrial marker porin confined to the cytoplasmic fraction. The two lanes show samples prepared from different culture plates. Blots are representative of 3 independent experiments.
###end p 40
###begin p 41
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 519 526 519 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g003">Fig. 3A</xref>
PARG activity in situ was evaluated by assessing PAR levels at several time points after inducing PARP-1 activation with the DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). In cultures treated with control PMO, PAR immunoreactivity peaked at 40-60 minutes after MNNG incubation and fell to baseline within 2 hours. In cultures treated with antisense PARG PMO, PAR immunoreactivity peaked at about 60 minutes and remained detectable for up to 4 hours, consistent with diminished nuclear PARG activity (Fig. 3A). The PAR immunostaining was confined to the nucleus in both control and antisense-treated cultures. Of note, nuclear condensation was apparent at the 4 hour time point in cultures treated with control PMO, but not antisense PARG PMO.
###end p 41
###begin title 42
PARG antisense PMO slows PAR degradation.
###end title 42
###begin p 43
###xml 1055 1062 1047 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g003">Fig. 3B</xref>
Cultures were incubated with 50 microM MNNG. For observations at time points of 60 minutes or less, incubation with MNNG was continuous. For observations at time points beyond 60 minutes, MNNG was washed out at the 60-minute time point. (A) Immunostaining for PAR (green) in astrocytes at the designated time points. Nuclei are counterstained red with propidium iodide, and the images are merged. The cultures treated with antisense PARG PMO show prolonged nuclear PAR immunostaining relative to those treated with control PMO, and show less nuclear condensation at the 4 hour time point. Scale bar = 40 microm. Results are representative of 4 independent experiments. (B) PAR Western blots from cells treated with MNNG show prolonged elevations in PAR immunoreactivity in the cultures treated with PARG antisense PMO. (C) Graph shows quantified data. n = 3, *p<0.05. (D) PAR Western blots prepared from nuclear and cytoplasmic cell fractions showed PAR detectable only in the nuclear fraction. These blots are overexposed, relative to the blots shown in Fig. 3B, to increase sensitivity.
###end p 43
###begin p 44
###xml 306 316 306 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g003">Fig. 3B, D</xref>
###xml 365 368 365 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Alano1">[5]</xref>
###xml 370 373 370 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Koh1">[6]</xref>
###xml 745 752 745 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g003">Fig. 3C</xref>
###xml 1010 1017 1010 1017 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g003">Fig. 3D</xref>
PAR western blots were also used to evaluate the time course of PAR formation. Cells treated with MNNG showed a distinct band of PAR immunoreactivity at 116 kD, corresponding to PARP-1 auto-modification, along with less distinct labeling of proteins at a range of molecular weights, generally above 85 kD (Fig. 3B, D). This pattern is consistent with prior reports [5], [6]. Western blots prepared from cell lysates prepared at serial time points after MNNG exposure showed a time course of PAR formation and degradation pattern similar to that observed with immunostaining. These serial evaluations also showed the peak level of PAR formation to be lower in the cells treated with PARG antisense PMO than in the cells treated with control PMO (Fig. 3C). In agreement with the immunostaining results, western blots performed on nuclear and cytoplasmic cell fractions showed abundant PAR in the nuclear fractions but no detectable PAR in the cytoplasm of either the control or antisense PMO - treated cultures (Fig. 3D). These findings support the results obtained with the enzymatic assays indicating a reduction in nuclear, but not cytoplasmic PARG activity in the antisense-treated cultures.
###end p 44
###begin p 45
###xml 61 68 61 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g003">Fig. 3A</xref>
###xml 182 188 182 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g004">Fig. 4</xref>
Consistent with the reduced nuclear condensation observed in Fig. 3A, cells treated with PARG antisense PMO showed reduced cell death when evaluated 24 hours after MNNG incubations (Fig. 4). The magnitude of this effect was comparable to that achieved with the PARP inhibitor 3, 4-dihydro-5-[4-(1-piperidinyl)butoxy]-1(2H)-isoquinolinone (DPQ), suggesting a near-complete abrogation of PARP-1 - mediated cell death by the antisense PARG PMO.
###end p 45
###begin title 46
PARP-1 mediated cell death is reduced by PARG antisense PMO.
###end title 46
###begin p 47
Cell survival was assessed 24 hours after 60-minute incubations with 50 microM MNNG. Cell death was comparably reduced by co-incubation with the PARP inhibitor, DPQ. Data shown are representative of 5 experiments, each with n = 3. **p<0.01 vs. 50 microM MNNG alone.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 655 658 655 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 660 664 660 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-MeyerFicca1">[21]</xref>
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
Primary mouse astrocytes were treated with an antisense PMO targeted to exon 1 of full-length PARG to suppress expression of this nuclear-specific PARG isoform. The antisense-treated cells showed down-regulation of both nuclear PARG immunoreactivity and nuclear PARG enzymatic activity, without significant alteration in cytoplasmic PARG activity. When treated with the genotoxic agent MNNG to induced PARP-1 activation, the antisense-treated cells showed a delayed rate of nuclear PAR degradation, reduced nuclear condensation, and reduced cell death. These findings support prior reports that full-length PARG is preferentially localized to the nucleus [7], [21], and provide a novel tool for investigating potential isoform-specific functions of PARG. These results also suggest a key role for nuclear PARG activity in PARP-1 - mediated cell death.
###end p 49
###begin p 50
###xml 108 115 108 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g001">Fig. 1A</xref>
###xml 313 316 313 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 318 321 318 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Niere1">[8]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-MeyerFicca1">[21]</xref>
###xml 669 672 669 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Bonicalzi1">[7]</xref>
###xml 674 678 674 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Haince1">[30]</xref>
The PARG gene can be processed into three splice variants that yield proteins of 111 kD, 102 kD, and 99 kD (Fig. 1A). Only the full length 111 kD PARG isoform is normally found in the cell nucleus, and this localization is attributed to a NLS motif encoded by the 5' region of exon 1 in the full length PARG mRNA [7], [8], [21]. The selective reduction in nuclear PARG activity observed in cells treated with antisense PMO targeting the 5' terminus of PARG exon 1 is thus consistent with a selective down-regulation of the full-length PARG isoform. However, evidence suggests that PARG normally found in the cytoplasm may under some conditions traffic into the nucleus [7], [30]. We thus cannot entirely exclude the possibility that the antisense treatment reduces expression of other PARG species with access to the nucleus, but the absence of any change in cytoplasmic PARG activity weighs against this possibility.
###end p 50
###begin p 51
###xml 226 230 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Summerton1">[31]</xref>
###xml 232 236 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Summerton2">[32]</xref>
###xml 471 475 471 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Summerton2">[32]</xref>
###xml 477 481 477 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Morcos1">[33]</xref>
The morpholino PMO antisense approach used here to suppress nuclear PARG protein expression differs from siRNA and other antisense approaches in that it inhibits mRNA translation by a mechanism independent of mRNA destruction [31], [32]. Antisense PMOs have previously been used to selectively suppress translation of splice variant mRNA species, and evidence suggests that the PMO antisense approach has less off-target effects than siRNA and other antisense approaches [32], [33]. Nevertheless, the results presented here cannot entirely exclude the possibility the antisense PMO directed against the full-length PARG affects nuclear PARG activity by a mechanism independent of PARG protein expression, but the selective loss of nuclear PARG activity without loss of cytoplasmic PARG activity again weighs against this possibility.
###end p 51
###begin p 52
###xml 515 522 515 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0004896-g003">Fig. 3C</xref>
###xml 585 588 585 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Zahradka1">[2]</xref>
###xml 1045 1049 1045 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Keil1">[34]</xref>
###xml 1051 1055 1051 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Gao1">[35]</xref>
Cellular PAR levels are the net result of the competing processes of PAR formation, primarily by PARP-1, and PAR degradation, by PARG. The prolonged increase in cellular PAR levels following MNNG-induced PARP-1 activation observed in cultures treated with antisense PARG PMO is consistent with reduced nuclear PARG activity. However, a somewhat surprising result was that the peak level of PAR formation was not elevated in these cultures, and was in fact reduced relative to the cultures treated with control PMO (Fig. 3C). Given that PARP-1 can be inhibited by PAR auto-modification [2], it is possible that the reduced peak PAR level observed in the PARG antisense-treated cultures is due to increased or prolonged PAR formation on PARP-1 with resultant reduced PARP-1 activity in these cultures. Reduced PARP-1 activity might also contribute to the reduced cell death observed in the antisense PARG-treated cultures. However, recent studies have also identified complex physical interactions between PARP-1, PARG, and other nuclear proteins [34], [35], and these findings raise the alternative possibilities that reduced nuclear PARG protein could influence PARP-1 activity by through these or other, more indirect interactions.
###end p 52
###begin p 53
###xml 489 492 489 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Alano1">[5]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Ying1">[10]</xref>
###xml 500 504 500 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Kim1">[11]</xref>
###xml 506 510 506 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sevigny1">[24]</xref>
###xml 512 516 512 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-SpinaPurrello1">[36]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Sheline1">[38]</xref>
Confluent primary astrocytes cultures are a useful model for these studies because these cells are homogeneous, differentiated, slowly-dividing, and non-neoplastic, with a correspondingly low level of spontaneous apoptosis. Astrocytes are the most numerous cell type in mammalian brain. Prior studies have extensively characterized the PARP-1 - mediated cell death pathway in this cell type, and shown that PARP-1 - mediated cell death can be attenuated by pharmacological PARG inhibitors [5], [10], [11], [24], [36]-[38].
###end p 53
###begin p 54
###xml 273 276 273 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Koh1">[6]</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Cortes1">[19]</xref>
###xml 831 835 831 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Cortes1">[19]</xref>
###xml 837 841 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Cozzi1">[20]</xref>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Gao1">[35]</xref>
###xml 1112 1116 1112 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Blenn1">[16]</xref>
###xml 1355 1356 1355 1356 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1357 1358 1357 1358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1727 1731 1727 1731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Jaiswal1">[39]</xref>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
###xml 311 316 <span type="species:ncbi:10090">mouse</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 663 667 <span type="species:ncbi:10090">mice</span>
###xml 1089 1096 <span type="species:ncbi:4460|species:ncbi:28478|species:ncbi:4456">Malanga</span>
Results of the present study can be compared to recent reports in which PARG protein expression was reduced by other methods in other model systems. Ablation of PARG enzymatic activity by gene disruption in the mouse causes massive PAR accumulation and embryonic lethality [6]. Cortes et al. generated a viable mouse in which a truncated 60 kDa PARG enzyme was expressed in place of the full length 110 kDa enzyme as a result of the targeted deletion of the exons 2 and 3 in the regulatory domain [19]. Cells from these mice showed reduced PARG activity in the nuclei, but markedly increased activity in the mitochondrial fraction. Surprisingly, cells from these mice showed evidence of reduced, rather than increased auto-modification of PARP-1, possibly due to abnormal interaction between the truncated PARG and PARP-1 or XRCC1 [19], [20], [35]. The reduced PARP-1 auto-modification was associated with increased cell death and mortality under conditions that trigger PARP-1 induced cell death. Most germane to the present study is the siRNA knockdown of PARG in HeLa cells reported by Malanga and colleagues [16]. These authors achieved a roughly 85% reduction in PARG enzymatic activity in both the cytoplasmic and nuclear compartments. Cells with reduced PARG activity showed prolonged PAR immunoreactivity and reduced cell death after exposure to H2O2, similar to the findings reported here with selective down-regulation of nuclear PARG activity. However, in contrast to the present results, PARG down-regulation did not increase viability in response to MNNG, a difference that may be attributable to PARP-1 - independent cell death pathways that can be triggered in dividing tumor cells by low concentrations of MNNG [39] or to the reduction in cytoplasmic PARG activity in the siRNA study.
###end p 54
###begin p 55
###xml 302 305 302 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Yu1">[4]</xref>
###xml 321 322 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 424 427 424 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Alano1">[5]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0004896-Kraus1">[40]</xref>
The present results indicate that selective reduction of nuclear PARG activity can attenuate PARP-1-induced astrocyte death, but the mechanism of this effect remains to be established. Given what is known about PARP-1 cell death pathway, possibilities include 1) slowed PAR liberation from the nucleus [4] ; 2) slowed NAD+ consumption, due to reducing PAR turnover at acceptor sites or to increased PARP-1 auto-modification [5]; and 3) effects on PAR-regulated transcription factors [40]. Further work will be required to distinguish between these or other possibilities.
###end p 55
###begin p 56
We thank Philippe Garnier and Mary Sevigny for assistance with these studies.
###end p 56
###begin title 57
References
###end title 57
###begin article-title 58
Poly(ADP-ribose): novel functions for an old molecule.
###end article-title 58
###begin article-title 59
A shuttle mechanism for DNA-protein interactions. The regulation of poly(ADP-ribose) polymerase.
###end article-title 59
###begin article-title 60
Role of poly(ADP-ribose) synthetase in inflammation and ischaemia- reperfusion.
###end article-title 60
###begin article-title 61
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor.
###end article-title 61
###begin article-title 62
Poly(ADP-ribose) polymerase-1-mediated cell death in astrocytes requires NAD+ depletion and mitochondrial permeability transition.
###end article-title 62
###begin article-title 63
Failure to degrade poly(ADP-ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality.
###end article-title 63
###begin article-title 64
Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when?
###end article-title 64
###begin article-title 65
Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix.
###end article-title 65
###begin article-title 66
Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase.
###end article-title 66
###begin article-title 67
Poly(ADP-ribose) glycohydrolase mediates oxidative and excitotoxic neuronal death.
###end article-title 67
###begin article-title 68
The role of NADPH oxidase and neuronal nitric oxide synthase in zinc- induced poly(ADP-ribose) polymerase activation and cell death in cortical culture.
###end article-title 68
###begin article-title 69
Cytoprotective effect of gallotannin in oxidatively stressed HaCaT keratinocytes: the role of poly(ADP-ribose) metabolism.
###end article-title 69
###begin article-title 70
###xml 87 90 <span type="species:ncbi:10116">rat</span>
Post-treatment with a novel PARG inhibitor reduces infarct in cerebral ischemia in the rat.
###end article-title 70
###begin article-title 71
The role of NADPH oxidase, neuronal nitric oxide synthase and poly(ADP ribose) polymerase in oxidative neuronal death induced in cortical cultures by brain-derived neurotrophic factor and neurotrophin-4/5.
###end article-title 71
###begin article-title 72
Poly(ADP-ribose) glycohydrolase activity mediates post-traumatic inflammatory reaction after experimental spinal cord trauma.
###end article-title 72
###begin article-title 73
Poly(ADP-ribose) glycohydrolase silencing protects against H2O2-induced cell death.
###end article-title 73
###begin article-title 74
Mono-galloyl glucose derivatives are potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors and partially reduce PARP-1-dependent cell death.
###end article-title 74
###begin article-title 75
###xml 31 53 <span type="species:ncbi:6239">Caenorhabditis elegans</span>
Altered DNA damage response in Caenorhabditis elegans with impaired poly(ADP-ribose) glycohydrolases genes expression.
###end article-title 75
###begin article-title 76
###xml 134 138 <span type="species:ncbi:10090">mice</span>
Depletion of the 110-kilodalton isoform of poly(ADP-ribose) glycohydrolase increases sensitivity to genotoxic and endotoxic stress in mice.
###end article-title 76
###begin article-title 77
###xml 123 127 <span type="species:ncbi:10090">mice</span>
Poly(ADP-ribose) accumulation and enhancement of postischemic brain damage in 110-kDa poly(ADP-ribose) glycohydrolase null mice.
###end article-title 77
###begin article-title 78
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments.
###end article-title 78
###begin article-title 79
###xml 68 78 <span type="species:ncbi:10141">guinea pig</span>
Purification and properties of an (ADP-ribose)n glycohydrolase from guinea pig liver nuclei.
###end article-title 79
###begin article-title 80
###xml 52 58 <span type="species:ncbi:9913">bovine</span>
Isolation and characterization of the cDNA encoding bovine poly(ADP- ribose) glycohydrolase.
###end article-title 80
###begin article-title 81
Expression and activity of poly(ADP-ribose) glycohydrolase in cultured astrocytes, neurons, and C6 glioma cells.
###end article-title 81
###begin article-title 82
Cell cultures.
###end article-title 82
###begin article-title 83
Rapid assay of poly(ADP-ribose) glycohydrolase.
###end article-title 83
###begin article-title 84
Molecular heterogeneity and regulation of poly(ADP-ribose) glycohydrolase.
###end article-title 84
###begin article-title 85
Increased AP-1 DNA-binding activity and nuclear REF-1 accumulation in lead-exposed primary cultures of astrocytes.
###end article-title 85
###begin article-title 86
Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay.
###end article-title 86
###begin article-title 87
Dynamic relocation of poly(ADP-ribose) glycohydrolase isoforms during radiation-induced DNA damage.
###end article-title 87
###begin article-title 88
Morpholino antisense oligomers: the case for an RNase H-independent structural type [In Process Citation].
###end article-title 88
###begin article-title 89
Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity.
###end article-title 89
###begin article-title 90
Achieving targeted and quantifiable alteration of mRNA splicing with Morpholino oligos.
###end article-title 90
###begin article-title 91
MNNG-induced cell death is controlled by interactions between PARP-1, poly(ADP-ribose) glycohydrolase, and XRCC1.
###end article-title 91
###begin article-title 92
Altered poly(ADP-ribose) metabolism impairs cellular responses to genotoxic stress in a hypomorphic mutant of poly(ADP-ribose) glycohydrolase.
###end article-title 92
###begin article-title 93
Effect of growth factors on nuclear and mitochondrial ADP-ribosylation processes during astroglial cell development and aging in culture.
###end article-title 93
###begin article-title 94
Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders.
###end article-title 94
###begin article-title 95
Involvement of poly ADP ribosyl polymerase-1 in acute but not chronic zinc toxicity.
###end article-title 95
###begin article-title 96
N-methyl-N'-nitro-N-nitrosoguanidine-induced senescence-like growth arrest in colon cancer cells is associated with loss of adenomatous polyposis coli protein, microtubule organization, and telomeric DNA.
###end article-title 96
###begin article-title 97
Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation.
###end article-title 97
###begin p 98
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 98
###begin p 99
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by the U.S. Dept. of Veterans Affairs and by the NIH (RO1 NS41421; RAS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 99

